Key Takeaways for pharmacists: Shingles Vaccination & Potential Broader Health Benefits
Here’s a summary of the details provided, geared towards pharmacists, outlining what they should know and how to counsel patients:
Core Message: Shingles vaccination may offer benefits beyond rash prevention, possibly reducing the risk of cardiovascular events and dementia. However, this should be communicated as an association and not a direct causal relationship.
what Pharmacists Should Know:
* Beyond rash Prevention: Data suggests shingles, even uncomplicated cases, is linked to increased risk of thrombo-ischemic events and vascular cognitive diagnoses even after the acute phase.
* systemic Signal: Consider shingles as a potential systemic signal, not just a localized skin issue.
* Real-World Evidence: Real-world data supports proactive patient counseling about both shingles prevention and these potential broader health benefits.
* Enhance Uptake: Pharmacists can play a key role in increasing vaccination rates through:
* Identifying eligible patients
* Using reminders
* Providing structured counseling
* Documenting vaccinations to contribute to real-world evidence.
Practical Messaging for Patients:
* Zoster-Naïve Patients (Never had Shingles): “Shingles vaccination helps prevent shingles,and in large real-world datasets it has also been linked with lower rates of major cardiovascular events and dementia diagnoses compared with another common adult vaccine.”
* Patients Who Have Had Shingles: “Your shingles episode might potentially be a cue to optimize cardiovascular risk factors and preventive care.Vaccination is still importent to reduce recurrence,and,in our analyses,the association with better downstream outcomes was not confined to people vaccinated only before shingles.”
Critically important Nuances to Communicate:
* Not Causation: Avoid framing it as “shingles causes heart attacks or dementia.” Focus on the association observed in the data.
* Trajectory Modification: Vaccination may modify disease trajectories, but confounding factors are still possible.
* Vaccination Timing: protection appears similar whether vaccination occurs before or after a shingles episode, suggesting it’s not solely about preventing the initial rash.
Confidence in Applying Findings:
* Strong Generalizability: The study involved a large, diverse patient population (111 US health systems).
* Robust Methodology: Researchers used methods to minimize bias (propensity score matching, delayed-entry designs).
* Consistent Results: Findings were consistent across various analyses.
Cautions & Considerations:
* Observational Data: Residual confounding is possible due to unmeasured factors.
* Data Limitations: vaccination records outside health systems may be incomplete, and outcome coding can be imperfect.
In essence, pharmacists can confidently use this information to enhance patient counseling, emphasizing the potential for broader health benefits alongside shingles prevention, while maintaining a nuanced and cautious approach.
